VANDA PHARMACEUTICALS INC. Cash and Cash Equivalents, Period Increase (Decrease)
VANDA PHARMACEUTICALS INC. (VNDA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$6.80 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-15
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $11.04M, a 44.12% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $8.35M, a 12.72% decline year-over-year.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$5.88M.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$20.32M.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$6.80M.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$10.42M.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$10.06M.
- VANDA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$3.86M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $11.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $19.39M derived: sum of 2 quarters · filed 2018-02-15 | $13.52M derived: sum of 3 quarters · filed 2018-02-15 | -$6.80M 10-K · filed 2018-02-15 |
| 2017-09-30 | $8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.48M derived: sum of 2 quarters · filed 2017-11-08 | -$17.84M 10-Q · filed 2017-11-08 | -$10.18M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | -$5.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$26.19M 10-Q · filed 2017-08-03 | -$18.53M derived: sum of 3 quarters · filed 2018-02-15 | -$8.96M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$20.32M 10-Q · filed 2017-05-03 | -$12.65M derived: sum of 2 quarters · filed 2018-02-15 | -$3.08M derived: sum of 3 quarters · filed 2018-02-15 | -$18.63M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $17.23M derived: sum of 2 quarters · filed 2018-02-15 | $1.69M derived: sum of 3 quarters · filed 2018-02-15 | -$10.42M 10-K · filed 2018-02-15 |
| 2016-09-30 | $9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.97M derived: sum of 2 quarters · filed 2017-11-08 | -$18.08M 10-Q · filed 2017-11-08 | -$14.02M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$15.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$27.65M 10-Q · filed 2017-08-03 | -$23.59M derived: sum of 3 quarters · filed 2018-02-15 | -$25.14M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$12.10M 10-Q · filed 2017-05-03 | -$8.05M derived: sum of 2 quarters · filed 2018-02-15 | -$9.60M derived: sum of 3 quarters · filed 2018-02-15 | $5.93M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $2.51M derived: sum of 2 quarters · filed 2018-02-15 | $18.03M derived: sum of 3 quarters · filed 2018-02-15 | -$10.06M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $13.98M derived: sum of 2 quarters · filed 2016-11-03 | -$14.12M 10-Q · filed 2016-11-03 | $31.48M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $15.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$12.56M 10-Q · filed 2016-07-28 | $33.03M derived: sum of 3 quarters · filed 2017-02-17 | $31.34M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$28.09M 10-Q · filed 2016-05-05 | $17.50M derived: sum of 2 quarters · filed 2017-02-17 | $15.81M derived: sum of 3 quarters · filed 2017-02-17 | -$10.45M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $45.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $43.91M derived: sum of 2 quarters · filed 2017-02-17 | $17.64M derived: sum of 3 quarters · filed 2017-02-17 | -$3.86M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$27.95M derived: sum of 2 quarters · filed 2015-11-04 | -$49.46M 10-Q · filed 2015-11-04 | -$126.86M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$26.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$47.77M 10-Q · filed 2015-07-31 | -$125.18M derived: sum of 3 quarters · filed 2016-02-12 | -$86.64M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$21.50M 10-Q · filed 2015-05-07 | -$98.91M derived: sum of 2 quarters · filed 2016-02-12 | -$60.37M derived: sum of 3 quarters · filed 2016-02-12 | -$66.67M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | -$77.41M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$38.87M derived: sum of 2 quarters · filed 2016-02-12 | -$45.17M derived: sum of 3 quarters · filed 2016-02-12 | -$24.01M 10-K · filed 2016-02-12 |
| 2013-09-30 | $38.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $32.24M derived: sum of 2 quarters · filed 2014-10-27 | $53.40M 10-Q · filed 2014-10-27 | $37.66M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | -$6.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $14.86M 10-Q · filed 2014-08-08 | -$882.00K derived: sum of 3 quarters · filed 2015-03-13 | $9.24M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $21.16M 10-Q · filed 2014-05-08 | $5.42M derived: sum of 2 quarters · filed 2015-03-13 | $15.54M derived: sum of 3 quarters · filed 2015-03-13 | $1.84M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | -$15.74M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$5.62M derived: sum of 2 quarters · filed 2015-03-13 | -$19.32M derived: sum of 3 quarters · filed 2015-03-13 | $849.00K 10-K · filed 2015-03-13 |
| 2012-09-30 | $10.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$3.58M derived: sum of 2 quarters · filed 2013-11-08 | $16.59M 10-Q · filed 2013-11-08 | $44.19M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$13.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $6.46M 10-Q · filed 2013-07-31 | $34.06M derived: sum of 3 quarters · filed 2014-02-25 | $44.00M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $20.17M 10-Q · filed 2013-05-10 | $47.77M derived: sum of 2 quarters · filed 2014-02-25 | $57.71M derived: sum of 3 quarters · filed 2014-02-25 | $55.57M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $27.60M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $37.54M derived: sum of 2 quarters · filed 2014-02-25 | $35.40M derived: sum of 3 quarters · filed 2014-02-25 | $45.36M 10-K · filed 2014-02-25 |
| 2011-09-30 | $9.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $7.81M derived: sum of 2 quarters · filed 2012-11-08 | $17.77M 10-Q · filed 2012-11-08 | -$42.14M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $7.83M 10-Q · filed 2012-08-03 | -$52.08M derived: sum of 3 quarters · filed 2013-02-26 | -$95.27M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $9.96M 10-Q · filed 2012-05-09 | -$49.95M derived: sum of 2 quarters · filed 2013-02-26 | -$93.13M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$59.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$103.09M derived: sum of 2 quarters · filed 2013-02-26 | -$162.74M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$43.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$102.83M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$59.64M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $166.22M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |